NIKKEI 225
39,588.01 +4.93 (+0.01%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
81.91 +0.37 (+0.45%) GOLD FUTURES
2,336.10 -3.50 (-0.15%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
50,034.84 +2,023.92 (+4.22%)
ORMP Nov 2024 5.000 call
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.1500 |
| Ask | 0.5000 |
| Strike | 5.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 98 |
PR NewswireOramed Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
- PR Newswire
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities
Simply Wall St.Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)
Oramed Pharmaceuticals ( NASDAQ:ORMP ) First Quarter 2024 Results Key Financial Results Net income: US$1.54m (up from...
